Larkspur Biosciences

Executive Summary

Larkspur Biosciences is a private biotechnology company headquartered in Cambridge, MA, founded in 2021 with a focus on developing first-in-class targeted protein degraders that disrupt cancer cell fitness pathways. By leveraging targeted degradation, the company aims to enhance cancer cell susceptibility to death mechanisms, particularly in difficult-to-treat indications such as microsatellite stable colorectal cancer (MSS-CRC). Larkspur's approach is rooted in immunology and oncology, seeking to destroy tumors by exploiting vulnerabilities in cellular fitness. As an early-stage private entity, Larkspur has not disclosed significant funding or valuation details, and its most advanced program is still in preclinical development. The company represents an emerging player in the protein degradation space, competing with larger firms but focusing on novel targets and mechanisms. While no clinical data have been released, the potential for addressing MSS-CRC—a large unmet need—provides a clear value proposition. However, given the early stage and lack of disclosed pipeline assets beyond the lead program, the near-term outlook is speculative and dependent on successful advancement to the clinic.

Upcoming Catalysts (preview)

• Q1 2027IND Filing for Lead Program in MSS-CRC40% success
• Q3 2026Presentation of Preclinical Proof-of-Concept Data at Major Oncology Conference70% success
• Q2 2027Series A or B Financing Round to Support Clinical Development60% success